FDA fast-tracks Abbvie's lung cancer drug
The investigational drug against non-small cell lung cancer can look forward to special treatment by the FDA, which has granted the drug Breakthrough Therapy Designation.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Abbvie starts out 2022 with positive news, as the US Food and Drug Administration (FDA) sees big potential in Abbvie's investigational antibody-drug conjugate, telisotuzumab vedotin.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
